2.76
price down icon1.08%   -0.03
after-market Dopo l'orario di chiusura: 2.74 -0.02 -0.72%
loading
Precedente Chiudi:
$2.79
Aprire:
$2.76
Volume 24 ore:
37,832
Relative Volume:
0.21
Capitalizzazione di mercato:
$93.39M
Reddito:
-
Utile/perdita netta:
$-13.27M
Rapporto P/E:
-16.83
EPS:
-0.164
Flusso di cassa netto:
$-7.70M
1 W Prestazione:
-4.83%
1M Prestazione:
+20.00%
6M Prestazione:
+162.86%
1 anno Prestazione:
+78.06%
Intervallo 1D:
Value
$2.74
$2.7983
Intervallo di 1 settimana:
Value
$2.67
$3.06
Portata 52W:
Value
$0.8075
$3.11

Okyo Pharma Limited Stock (OKYO) Company Profile

Name
Nome
Okyo Pharma Limited
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
4
Name
Cinguettio
Name
Prossima data di guadagno
2024-09-30
Name
Ultimi documenti SEC
Name
OKYO's Discussions on Twitter

Confronta OKYO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
OKYO
Okyo Pharma Limited
2.76 103.43M 0 -13.27M -7.70M -0.164
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Okyo Pharma Limited Borsa (OKYO) Ultime notizie

pulisher
Jul 24, 2025

Will OKYO Pharma Limited stock benefit from AI tech trendsExplosive market performance - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

What institutions are buying OKYO Pharma Limited stock nowConsistently exceptional gains - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain - Pharmafile

Jul 24, 2025
pulisher
Jul 23, 2025

What drives OKYO Pharma Limited stock priceAccelerated wealth expansion - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is OKYO Pharma Limited a good long term investmentPhenomenal trading returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

OKYO Pharma Limited Stock Analysis and ForecastSuperior portfolio returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about OKYO Pharma Limited stockRapid-fire capital growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

OKYO Pharma Secures $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - VisionMonday.com

Jul 21, 2025
pulisher
Jul 19, 2025

OKYO Pharma CEO details positive results from Phase 2 urcosimod trialICYMI - Proactive financial news

Jul 19, 2025
pulisher
Jul 18, 2025

OKYO Pharma Secures $1.9M Non-Dilutive Funding to Advance Urcosimod Development - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain - Ophthalmology Times

Jul 18, 2025
pulisher
Jul 17, 2025

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding - GlobeNewswire

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma receives $1.9 million non-dilutive funding for lead drug development - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 17, 2025

Small cap wrap: Digi Power X, American Resources, OKYO Pharma, Lisata Therapeutics... - Proactive financial news

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Slides Despite Fresh R&D Funding - Baystreet.ca

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Okyo Pharma Obtains $1.9 Million Non-Dilutive Funding - MarketScreener

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing - Proactive financial news

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO’s Market Whiplash: 86.16% YTD Rise, -1.66% Plunge in 30 Days - investchronicle.com

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - MarketScreener

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Secures $1.9M to Fast-Track Revolutionary Eye Pain Drug with No Current FDA Treatment - Stock Titan

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data - Investing.com Australia

Jul 17, 2025
pulisher
Jul 16, 2025

OKYO Pharma Limited Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - MarketScreener

Jul 16, 2025
pulisher
Jul 16, 2025

OKYO Pharma Receives Positive Buy Rating from H.C. Wainwright - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

OKYO posts trial data for lead drug in eye pain (OKYO:NASDAQ) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

OKYO Pharma reports positive Phase 2 data in treating Neuropathic Corneal Pain - Proactive financial news

Jul 16, 2025
pulisher
Jul 16, 2025

Small cap wrap: OKYO Pharma, North Bay Resources, Nevis Brands, Nextech3D.ai... - Proactive financial news

Jul 16, 2025
pulisher
Jul 16, 2025

OKYO Pharma Says Phase 2 Study of Urcosimod Showed 'Marked Reduction' in Neuropathic Corneal Pain Scores - MarketScreener

Jul 16, 2025
pulisher
Jul 16, 2025

OKYO Pharma stock surges after positive Phase 2 results for eye pain drug - Investing.com Australia

Jul 16, 2025
pulisher
Jul 16, 2025

OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

OKYO Pharma reports positive top-line results from Phase 2 urcosimod trial - Investing.com Nigeria

Jul 16, 2025

Okyo Pharma Limited Azioni (OKYO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):